ArticleMedical oncology (Northwood, London, England)2013
Effects of EHD2 interference on migration of esophageal squamous cell carcinoma.
Article in Medical oncology (Northwood, London, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 35 citations in OpenAlex.
- A Quarter Century of EHD Protein Research: From Endosomal Recycling to Ciliopathies.Traffic (Copenhagen, Denmark) · 2026Review
- Caveolae in cancer: mechanochemical signaling in tumor progression, immunity, and therapy.Cell communication and signaling : CCS · 2026Review
- Endocytosis in cancer and cancer therapy.Nature reviews. Cancer · 2023Review
- Article
- Article
- circEPS15 Overexpression in Hepatocellular Carcinoma Modulates Tumor Invasion and Migration.Frontiers in genetics · 2022Article
- Ese-3 contributes to colon cancer progression by downregulating EHD2 and transactivating INPP4B.American journal of cancer research · 2021Article
- TUSC8 inhibits the development of osteosarcoma by sponging miR‑197‑3p and targeting EHD2.International journal of molecular medicine · 2020Article
- Cross-Species Proteomics Identifies CAPG and SBP1 as Crucial Invasiveness Biomarkers in Rat and Human Malignant Mesothelioma.Cancers · 2020Article
- Caveolin-1 function at the plasma membrane and in intracellular compartments in cancer.Cancer metastasis reviews · 2020Review
- EHD2 is a Predictive Biomarker of Chemotherapy Efficacy in Triple Negative Breast Carcinoma.Scientific reports · 2020Article
- Covariance-Insured Screening.Computational statistics & data analysis · 2019Article
- EHD2 is a mechanotransducer connecting caveolae dynamics with gene transcription.The Journal of cell biology · 2018Article
- A muscle-specific protein 'myoferlin' modulates IL-6/STAT3 signaling by chaperoning activated STAT3 to nucleus.Oncogene · 2017Article
- Prognostic implication of histological features associated with EHD2 expression in papillary thyroid carcinoma.PloS one · 2017Article
- Decreased Expression of EHD2 Promotes Tumor Metastasis and Indicates Poor Prognosis in Hepatocellular Carcinoma.Digestive diseases and sciences · 2016Article
- Up-regulation of SPOCK1 induces epithelial-mesenchymal transition and promotes migration and invasion in esophageal squamous cell carcinoma.Journal of molecular histology · 2015Article
- Role of EHD2 in migration and invasion of human breast cancer cells.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Decreased expression and prognostic role of EHD2 in human breast carcinoma: correlation with E-cadherin.Journal of molecular histology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
C-Terminal EH domain-containing protein 2 (EHD2) of the EHD family is associated with plasma membrane. We investigated the expression of EHD2 in human esophageal squamous cell carcinoma (ESCC) and the EHD2 expression to study the therapeutic effect of chemotherapy drugs. Western blot and immunohistochemistry were used to measure the expression of EHD2 protein in ESCC and adjacent normal tissue in 98 patients. EHD2 protein level was reduced in ESCC tissues in comparison with adjacent normal tissues. Under-expression of EHD2 increased the motility property of ESCC cell TE1 in vitro by wound-healing assays and transwell migration assays, and it was concurrent with the decreased expression of epithelial marker E-cadherin. Under-expression of EHD2 in TE1 can cause resistance to cisplatin. Our results suggested that EHD2 low expression is involved in the pathogenesis of ESCC, and it might be a favorable independent poor prognostic parameter for ESCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.